Watch MDS members Bas Bloem, Claudia Trenkwalder and Angelo Antonini discuss new strategies and hope for Parkinson's disease. @ctrenkwalder1@basbloem@angelo_antonini
Deep dive into #ParkinsonsDisease research at #MDSCongress 🧠💡
@angelo_antonini (@UniPadova) discussed key findings from the Phase IIb study on mesdopetam's efficacy and the transformative effects of foslevodopa/foscarbidopa SC infusion for advanced Parkinson’s disease.
🔜 on https://t.co/QTD4sw3bMb
@AlbertoEspay BACE inhibitors did reduce Abeta42 in the CSF but also worsened cognition! The opposed happened with lecanemab: “do not through the baby out with the bathwater” 😎
The 'toxic amyloid' #Alzheimers dogma:
𝟒𝟏 Trials didn't reduce amyloid enough.
"The hypothesis wasn't really tested!"
𝟏 Trial reduced it to just the right level.
"The hypothesis is confirmed!"
What's invisible about lecanameb?
Accelerates brain atrophy
Increases CSF Aβ42
#Parkinsons is different for everyone 🌍 @angelo_antonini talks on providing a uniform evaluation of PD patients
MANAGE-PD: a tool to support HCPs in the identification of patients with uncontrolled symptoms: https://t.co/flmnLYMt7h
#WorldParkinsonsDay@movedisorder
Just learned about #PD_Pal through this great conversation between @DrISubramanian and
@angelo_antonini - European initiative looking into a new model of #PalliativeCare care for #PD patients.
Is anything similar happening in the US?
We need this!
https://t.co/OFwRmINU6X